# Neuralink — Healthcare Investment Intelligence

> other · Series C+. MedFuel Intel profile as of 2026-06-12.

Neuralink has raised over $158 million by 2019, including $100 million from Elon Musk, and continued with multiple funding rounds including Series B and later stages to support clinical trials and development of implantable brain-computer interfaces. The company received FDA approval in May 2023 for human trials and is conducting the PRIME Study for patients with spinal cord injuries or ALS.[1][2]

## Key facts (as of 2026-06-12)
- Sector: other
- Stage: Series C+
- Website: https://neuralink.com

## MedFuel assessment
- Intelligence score: 0/100
- Analyses: 0
- Sentiment trend: stable

---
Source: MedFuel Intel — https://medfuelintel.com/company/neuralink-14. Figures reflect MedFuel's analysis; verify against primary sources (SEC, FDA, ClinicalTrials.gov) before any investment decision.